Comments
Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating Parkinson’s symptoms which inclue shakiness, stiffness and difficulty in moving.
Zydus Cadila has received final approval from the USFDA to market Carbidopa tablets (25 mg), the company said in a BSE filing today.
The approved product will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The Zydus group has more than 190 approvals and so far filed over 320 abbreviated new drug applications (ANDAs) since it had started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading down by 0.67 per cent at Rs 397.80 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.